Tesamorelin Cycle and Protocol: What Researchers Actually Use

Tesamorelin at a glance:

• Drug class: GHRH analog
• Manufacturer: Theratechnologies
• FDA approved: 2010
• Route: subcutaneous injection
• Typical frequency: once daily
• Half-life: approximately 26-38 minutes
• Cash price (US): $3,000-$4,000/month without insurance

If you're researching Tesamorelin cycles, the honest framing is: what are researchers using, and why aren't there structured human trials of long-term cycling protocols? We answer both.

What "Cycle" Means in Peptide Discussions

In research-peptide and GHS communities, a "cycle" usually refers to a defined period of administration (often 8-12 weeks) followed by a break. The rationale draws on receptor desensitization theory and historical bodybuilding practice.

For Tesamorelin: any cycling pattern outside the labeled indication is off-label and not evidence-based.

Published Research Dosing

Approved dose is 2 mg subcutaneously once daily.

When peptides are studied in research, the doses come from animal-to-human translation, prior pharmacokinetic data, and trial designs that can't be assumed to apply to individual self-administration.

What Researchers Actually Do

In the published research literature on Tesamorelin:

• Doses are typically expressed in mcg/kg or fixed mg amounts
• Administration routes match what was tested for safety
• Duration is bounded by the trial protocol (often 8-12 weeks)
• Outcome measurement is structured and pre-specified

These are not personal protocols; they're trial designs.

Why We Don't Publish Self-Administration Protocols

Three reasons:

1. Compound purity and identity are not verifiable for material from grey-market sources
2. Individual response to non-FDA-approved compounds is not characterized at the population level
3. Liability and safety realities make specific instructions inappropriate for an informational site

For Tesamorelin specifically, the evidence base is too thin to support specific guidance.

What to Do Instead

If you're researching Tesamorelin because of a specific health goal, the more productive path is usually:

• Identify the underlying issue (musculoskeletal, metabolic, etc.)
• Look at FDA-approved options that address it
• Talk to a clinician with relevant expertise
• Consider research-peptide options only as a last resort, with clear understanding of unknowns

Risks to Understand

• fluid retention
• carpal tunnel syndrome
• glucose intolerance

These are compound to the risks of unregulated supply (purity, contamination, dosing accuracy).

Bottom Line

If you're considering self-administering Tesamorelin, the most useful thing this page can do is point you toward FDA-approved alternatives that address the same goal with characterized risk.

Frequently Asked Questions

Related Reading

• Is Tesamorelin Right for You? An Evidence-Based Breakdown
• Is Tesamorelin Safe? An Honest Look at the Side-Effect Profile
• Tesamorelin Results: What the Real Numbers Show in 2026
• Why Tesamorelin Costs So Much (and 5 Ways to Pay Less)
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.

This page is informational only and is not medical advice or a recommendation for self-administration of any compound.